ANL 13.55 Decreased By ▼ -0.79 (-5.51%)
ASC 13.32 Decreased By ▼ -0.63 (-4.52%)
ASL 14.02 Decreased By ▼ -1.08 (-7.15%)
BOP 8.36 Decreased By ▼ -0.16 (-1.88%)
BYCO 6.14 Decreased By ▼ -0.40 (-6.12%)
FCCL 17.61 Decreased By ▼ -1.19 (-6.33%)
FFBL 24.90 Decreased By ▼ -1.95 (-7.26%)
FFL 10.25 Decreased By ▼ -0.75 (-6.82%)
FNEL 9.80 Decreased By ▼ -0.71 (-6.76%)
GGGL 15.30 Decreased By ▼ -0.95 (-5.85%)
GGL 29.50 Decreased By ▼ -2.00 (-6.35%)
HUMNL 5.90 Decreased By ▼ -0.34 (-5.45%)
JSCL 16.00 Decreased By ▼ -0.89 (-5.27%)
KAPCO 32.05 Decreased By ▼ -1.05 (-3.17%)
KEL 3.17 Decreased By ▼ -0.10 (-3.06%)
MDTL 2.21 Decreased By ▼ -0.06 (-2.64%)
MLCF 34.39 Decreased By ▼ -2.71 (-7.3%)
NETSOL 95.50 Decreased By ▼ -7.30 (-7.1%)
PACE 4.25 Decreased By ▼ -0.43 (-9.19%)
PAEL 21.43 Decreased By ▼ -1.72 (-7.43%)
PIBTL 7.60 Decreased By ▼ -0.26 (-3.31%)
POWER 6.60 Decreased By ▼ -0.45 (-6.38%)
PRL 12.69 Decreased By ▼ -0.97 (-7.1%)
PTC 8.75 Decreased By ▼ -0.15 (-1.69%)
SILK 1.25 Decreased By ▼ -0.06 (-4.58%)
SNGP 38.68 Decreased By ▼ -3.02 (-7.24%)
TELE 15.88 Decreased By ▼ -1.11 (-6.53%)
TRG 81.73 Decreased By ▼ -6.02 (-6.86%)
UNITY 23.70 Decreased By ▼ -1.65 (-6.51%)
WTL 2.05 Decreased By ▼ -0.15 (-6.82%)
BR100 4,401 Decreased By ▼ -269.99 (-5.78%)
BR30 17,494 Decreased By ▼ -1340.29 (-7.12%)
KSE100 43,234 Decreased By ▼ -2134.99 (-4.71%)
KSE30 16,698 Decreased By ▼ -877.9 (-4.99%)

Coronavirus
LOW Source: covid.gov.pk
Pakistan Deaths
28,745
824hr
Pakistan Cases
1,285,631
37724hr
0.85% positivity
Sindh
476,017
Punjab
443,240
Balochistan
33,488
Islamabad
107,765
KPK
180,146
World

UK halts trial of hydroxychloroquine as ‘useless’ for COVID-19 patients

  • Trump touted drug as potential "game changer"
  • UK trial shows it "doesn't work" against COVID-19
  • US randomised test also found drug to be ineffective
  • WHO says it will still resume tests of hydroxychloroquine
05 Jun 2020

LONDON: British scientists halted a major drug trial on Friday after it found that the anti-malarial hydroxychloroquine, touted by US President Donald Trump as a potential "game changer" in the pandemic, was "useless" at treating COVID-19 patients.

"This is not a treatment for COVID-19. It doesn't work," Martin Landray, an Oxford University professor who is co-leading the RECOVERY trial, told reporters.

"This result should change medical practice worldwide. We can now stop using a drug that is useless." Vocal support from Trump raised expectations for the decades-old drug that experts said could have been a cheap and widely available tool, if proven to work, in fighting the pandemic, which has infected more than 6.4 million people and killed nearly 400,000 worldwide.

Controversy surrounding the drug grew after a study published in medical journal The Lancet last month raised safety concerns and led several COVID-19 studies of it to be halted. The Lancet study was then retracted on Thursday after its authors said they were unsure about its data.

Landray, a professor of medicine and epidemiology at Oxford University, noted the "huge speculation" about the drug as a treatment for COVID-19 but said there had been until now "an absence of reliable information from large randomised trials".

He said the preliminary results from RECOVERY, which was a randomised trial, were now quite clear: hydroxychloroquine does not reduce the risk of death among hospitalised patients with COVID-19. "If you're admitted to hospital, don't take hydroxychloroquine," he said.

RANDOMISED TRIALS

The RECOVERY trial of hydroxychloroquine had randomly assigned 1,542 COVID-19 patients to hydroxychloroquine and compared them with 3,132 COVID-19 patients randomly assigned to standard care without the drug.

Results showed no significant difference in death rates after 28 days, in length of stay in hospital or in other outcomes, the researchers said.

Earlier this week, a University of Minnesota randomised trial found that the drug was ineffective in preventing infection in people exposed to the coronavirus.

Dozens of trials trying various permutations of use of the drug continue.

The World Health Organization (WHO) said on Friday the RECOVERY results would not change its plan to resume tests of hydroxychloroquine as part of its 'Solidarity' trials. It had briefly stopped giving it to new patients in light of the Lancet paper.

Parastou Donyai, director of Pharmacy Practice at the University of Reading in England, said the drug was "propelled onto the world stage by President Trump", adding he had praised it without solid evidence.

"This news, although not positive, is a welcome relief to thousands of scientists, doctors and academics who have been crying out for proper proof of whether hydroxychloroquine works in COVID-19 or not." she added, calling the conclusion that it does not "definitive".

We love hearing your feedback, please help us improve by answering these few survey questions

Comments

Comments are closed.